drugset
drugset / Trial / NCT01480245

Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

NCT01480245 ↗

Phase 3 Terminated 233 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore long-term safety, tolerability and efficacy of GSK2402968 in DMD subjects who previously participated in either DMD114117 or DMD114044.

Timeline

Start
2011-09
Primary completion
2014-03
Completion
2014-03

Outcome

Outcome not reported

Stopped: “The study was formally terminated given that GSK is not submitting an application for regulatory approval for drisapersen in Duchenne Muscular Dystrophy.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Drisapersen Antisense oligonucleotide 6 mg/kg —

Indications

muscular dystrophy